Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher S Jones

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
The identification of orally bioavailable thrombopoietin agonistsMichael J Munchhof, Amy S Antipas, Laura C Blumberg, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14Julian A Blagg, Mark C Noe, Lilli A Wolf-Gouveia, et al.
Journal of Medicinal Chemistry|December 14, 2012
Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119Etzer Darout, Ralph P Robinson, Kim F McClure, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13Kevin D Freeman-Cook, Lawrence A Reiter, Mark C Noe, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Bioorganic & Medicinal Chemistry Letters|February 3, 2009
The identification of orally bioavailable thrombopoietin agonistsMichael J Munchhof, Amy S Antipas, Laura C Blumberg, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2012
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitusJeffrey A Pfefferkorn, Meihua Tu, Kevin J Filipski, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2005
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14Julian A Blagg, Mark C Noe, Lilli A Wolf-Gouveia, et al.
Journal of Medicinal Chemistry|December 14, 2012
Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119Etzer Darout, Ralph P Robinson, Kim F McClure, et al.
Bioorganic & Medicinal Chemistry Letters|September 1, 2006
Potent, selective pyrimidinetrione-based inhibitors of MMP-13Lawrence A Reiter, Kevin D Freeman-Cook, Christopher S Jones, et al.
Bioorganic & Medicinal Chemistry Letters|October 16, 2007
Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13Kevin D Freeman-Cook, Lawrence A Reiter, Mark C Noe, et al.
Journal of Medicinal Chemistry|December 27, 2011
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitusJeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, et al.
Pageof 5